These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7748308)

  • 21. Evidence that changes in hippocampal excitability in vitro are caused by withdrawal from chronic in vivo ethanol administration.
    Morton B; Ripley TL; Whittington MA; Butterworth AR; Little HJ
    Alcohol Alcohol; 1992 Jan; 27(1):71-9. PubMed ID: 1316122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
    Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
    Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prospects of using calcium channel blockers in the treatment of alcoholism].
    Kostowski W
    Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):109-11. PubMed ID: 2216948
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacological studies on a new Dihydrothienopyridine calcium antagonist. 2nd communication: effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4- (3-nitrophenyl)thieno[2,3-b]pyridine-5-carboxylate on the 1,4-dihydropyridine binding sites in the brain and on isolated arteries in the Cynomolgus monkey.
    Nakajima M; Adachi I; Ueda M
    Arzneimittelforschung; 1993 Dec; 43(12):1276-82. PubMed ID: 8141814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic regulation of dihydropyridine-sensitive calcium channels in brain may determine susceptibility to physical dependence on alcohol.
    Brennan CH; Crabbe J; Littleton JM
    Neuropharmacology; 1990 May; 29(5):429-32. PubMed ID: 2162493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between increases in dihydropyridine binding in vivo and behavioural signs of ethanol withdrawal in mice.
    Watson WP; Little HJ
    Alcohol Alcohol; 1999; 34(1):35-42. PubMed ID: 10075399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cortical dihydropyridine binding sites are unaltered in human alcoholic brain.
    Kril JJ; Gundlach AL; Dodd PR; Johnston GA; Harper CG
    Ann Neurol; 1989 Sep; 26(3):395-7. PubMed ID: 2529812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nitrendipine, given during drinking, decreases the electrophysiological changes in the isolated hippocampal slice, seen during ethanol withdrawal.
    Whittington MA; Little HJ
    Br J Pharmacol; 1991 Jul; 103(3):1677-84. PubMed ID: 1933131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of prolonged exposure to ethanol in vivo on functional parameters and sensitivity to nitrendipine in the isolated rat heart.
    Guppy LJ; Littleton JM
    J Cardiovasc Pharmacol; 1999 Sep; 34(3):414-9. PubMed ID: 10471001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses.
    van Zwieten PA; Pfaffendorf M
    J Hypertens Suppl; 1993 Dec; 11(6):S3-8. PubMed ID: 8169379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Action of chlormethiazole in a model of ethanol withdrawal.
    Green AR; Davies EM; Little HJ; Whittington MA; Cross AJ
    Psychopharmacology (Berl); 1990; 102(2):239-42. PubMed ID: 2177205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
    Akizuki O; Inayoshi A; Kitayama T; Yao K; Shirakura S; Sasaki K; Kusaka H; Matsubara M
    Eur J Pharmacol; 2008 Apr; 584(2-3):424-34. PubMed ID: 18331727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrophysiological and radioligand binding studies of elgodipine and derivatives in portal vein myocytes.
    Lepretre N; Arnaudeau S; Mironneau J; Rakotoarisoa L; Mironneau C; Galiano A
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1209-15. PubMed ID: 7996428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of dihydropyridines on the components of the ethanol withdrawal syndrome: possible evidence for involvement of potassium, as well as calcium?
    Watson WP; Little JJ
    Alcohol Clin Exp Res; 1997 May; 21(3):409-16. PubMed ID: 9161599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dihydropyridine-sensitive calcium channels and barbiturate tolerance and withdrawal.
    Rabbani M; Brown J; Butterworth AR; Little HJ
    Pharmacol Biochem Behav; 1994 Mar; 47(3):675-80. PubMed ID: 8208788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Key roles of Phe1112 and Ser1115 in the pore-forming IIIS5-S6 linker of L-type Ca2+ channel alpha1C subunit (CaV 1.2) in binding of dihydropyridines and action of Ca2+ channel agonists.
    Yamaguchi S; Zhorov BS; Yoshioka K; Nagao T; Ichijo H; Adachi-Akahane S
    Mol Pharmacol; 2003 Aug; 64(2):235-48. PubMed ID: 12869628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperexcitability in adrenal cells after culture in ethanol: withdrawal or excitotoxicity.
    Ruhe C; Bouchenafa O; Davies R; Littleton J
    Alcohol Alcohol Suppl; 1993; 2():301-5. PubMed ID: 7748315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leuprolide: a luteinizing hormone releasing hormone agonist attenuates ethanol withdrawal syndrome and ethanol-induced locomotor sensitization in mice.
    Umathe SN; Bhutada PS; Dixit PV; Jain NS
    Neuropeptides; 2008 Jun; 42(3):345-53. PubMed ID: 18280564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment with isradipine, a calcium-channel blocker, does not attenuate the acute behavioral effects of ethanol in humans.
    Rush CR; Pazzaglia PJ
    Alcohol Clin Exp Res; 1998 Apr; 22(2):539-47. PubMed ID: 9581666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evaluation of the N-type channel blocking properties of cilnidipine and other voltage-dependent calcium antagonists.
    Nap A; Mathy MJ; Balt JC; Pfaffendorf M; van Zwieten PA
    Fundam Clin Pharmacol; 2004 Jun; 18(3):309-19. PubMed ID: 15147282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.